These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2569824)

  • 1. Selective alpha 1-adrenergic blockade, lipids, and coronary heart disease risk. Considerations in the treatment of mild hypertension.
    Graham RM
    Am J Med; 1989 Aug; 87(2A):53S-56S. PubMed ID: 2569824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein.
    Kincaid-Smith P
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral antihypertensive agents on blood lipid levels.
    Leren P
    Clin Ther; 1986; 8(3):309-19. PubMed ID: 2872961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive therapy: taking lipids into consideration.
    Grimm RH
    Am Heart J; 1991 Sep; 122(3 Pt 2):910-8. PubMed ID: 1678922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL
    Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and lipid lowering effects of terazosin.
    Rosenthal J
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():85-9; discussion 90-1. PubMed ID: 2575179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
    Davey MJ
    Am J Med; 1989 Aug; 87(2A):36S-44S. PubMed ID: 2569823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating hypertension and cardiovascular risk: are there trade-offs?
    Grimm RH
    Am Heart J; 1990 Mar; 119(3 Pt 2):729-32; discussion 732. PubMed ID: 1968699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties.
    Leren P
    Am J Med; 1987 Jan; 82(1A):31-5. PubMed ID: 2879461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of beta-adrenergic blocking agents on blood lipid levels.
    Wolinsky H
    Clin Cardiol; 1987 Oct; 10(10):561-6. PubMed ID: 2889552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive therapy and lipids. Paradoxical influences on cardiovascular disease risk.
    Weinberger MH
    Am J Med; 1986 Feb; 80(2A):64-70. PubMed ID: 2868658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications.
    Colucci WS
    Ann Intern Med; 1982 Jul; 97(1):67-77. PubMed ID: 6124197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antihypertensive agents on lipid metabolism.
    Cutler R
    Am J Cardiol; 1983 Feb; 51(4):628-31. PubMed ID: 6131603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of prazosin on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on coronary heart disease: hypertension and other risk factors, Milan, 1983.
    Lowenstein J
    Am J Cardiol; 1984 Jan; 53(3):21A-23A. PubMed ID: 6141723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.